April 30 (Reuters) - AstraZeneca said on Friday it
expected higher sales in the second half of the year, as it
reported first-quarter profit and sales ahead of analysts'
average expectations, including $275 million in COVID-19 vaccine
sales.
(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger
in Frankfurt; editing by John Stonestreet)